Migraine—Not Just a Numbers Game
Kopel D, Gottschalk C. Migraine—Not Just a Numbers Game. Neurology 2022, 100: 357-358. PMID: 36396450, DOI: 10.1212/wnl.0000000000201566.Peer-Reviewed Original ResearchConceptsPatient-reported outcome measuresSide effectsAbortive medication useMigraine-related qualityQuality of lifePrimary endpointPreventive therapyMedication useHeadache daysMigraine treatmentPatient populationTreatment optionsPreventive treatmentRecent trialsMigraine pathophysiologyNeurologic disordersDrug trialsOutcome measuresPatient confidenceMost headachesPrescription choicesClinical practicePatientsTherapyMore yearsThe importance of an early onset of migraine preventive disease control: A roundtable discussion
Gottschalk C, Basu A, Blumenfeld A, Torphy B, Marmura M, Pavlovic J, Dumas P, Lalvani N, Buse D. The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 2022, 5: 25158163221134593. DOI: 10.1177/25158163221134593.Peer-Reviewed Original ResearchEarly onsetDisease controlPreventive therapyMigraine activityAnti-calcitonin gene-related peptide monoclonal antibodyMigraine preventive therapyBurden of migrainePeptide monoclonal antibodyRoundtable of expertsMigraine preventionTreatment initiationPreventive benefitsClinical studiesTreatment expectationsClinical relevancePatientsDrug AdministrationPatient advocatesTherapy goalsHealthcare professionalsMonoclonal antibodiesRoundtable meetingPreventionGrey literatureProfessionals' perceptionsThe importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review
Gottschalk C, Buse DC, Marmura MJ, Torphy B, Pavlovic JM, Dumas PK, Lalvani N, Blumenfeld A. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Therapeutic Advances In Neurological Disorders 2022, 15: 17562864221095902. PMID: 35662957, PMCID: PMC9160905, DOI: 10.1177/17562864221095902.Peer-Reviewed Original ResearchMigraine preventionEarly onsetDay 1Migraine daysAvailable clinical trial evidenceAnti-CGRP monoclonal antibodiesFirst treatment weekMigraine preventive therapyMigraine preventive treatmentTraditional oral agentsWeekly migraine daysClinical trial evidenceLeast moderate severityPatient-level outcomesRelevant benefitsOnset preventionOral agentsPreventive therapyChronic migraineMigraine frequencyTrial evidenceTreatment weekPreventive treatmentModerate severityPreventive benefits